| Title: |
Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study |
| Authors: |
Rossolini, Gian M.; Dryden, Matthew S.; Kozlov, Roman S.; Quintana, Alvaro; Flamm, Robert K.; Läuffer, Jörg M.; Lee, Emma; Morrissey, Ian; on behalf of the CLASS study group; Fille, Manfred; Savov, Encho; Velinov, Tzvetan; Zemlicková, Helena; Ghaly, Farid; Cremniter, Julie; Donnio, Pierre Yves; Fauchere, Jean-Louis; Fosse, Thierry; Gutmann, Laurent; Jarlier, Vincent; Lannote, Philippe; Marchandin, Hélène; Maurin, Max; Pons, Jean Louis; Soussy, Claude-James; Tankovic, Jacques; Abele-Horn, Marianne; Gatermann, Sören; Günther; Jacobs, Enno; MacKenzie, Colin R.; Mai, Uwe; Mutters, Reinier; Pfister, Wolfgang; Schoerner, Christoph; Schmitz, Franz-Josef; Schubert, Sabine; Seifert, Harald; Malamou-Lada, Helen; Paniara, O.; Papaparaskevas, Joseph; Petropoulou, Dimitra Mylona; Vakalis, Nicholas; Smyth, Edmond; Moses, Allon; Rahav, Galia; Clerici, Pierangelo; Gesu, Giovanni; Giacomo, Fortina; Goglio, Antonio; Li Bergoli, Michele; Mario, Rassu; Nicoletti, Giuseppe; Nicoletti, Pierluigi; Repetto, Drssa Antonella; Rossolini, Gianmaria; Rubattu, Drssa Laura; Sambri, Vittorio; Sarti, Mario; Scarparo, Claudio; Spanò, Alberto; Buiting, A. G. M.; Cohen, Stuart; Kluijtmans, J; Mouton, J.; van Westreenen, Mireille; Heczko, Piotr; Hryniewicz, Waleria; Luczak, Miroslaw; Przondo-Mordarska, Anna; Sawicka-Grzelak, Anna; Cristino, Melo; Espinar, Dra Maria José; da Graça Ribeiro, Dra Maria; Koslov, Roman; Kotulová, Daniela; Alós, Dra; Aznar, Javier; Bouza, Emilio; Blanco, Javier; Brea; Canton, Rafael; Casal; Chaves, F.; García-Rodriguez; Linares; Marco; Pascual; Picazo; Gimeno, Concepción; Prats, Guillem; Revillo, Dra; Santos, Dra; Segovia; Perez-Trallero; Bille, Jacques; Frei, Reno; Mühlemann, Kathrin; Schrenzel, Jacques; Zbinden, Reinhard; Akdeniz, Hayrettin; Berktas, Mustafa; Balik, Ismail; Birengel, Serhat; Besirbellioglu, Bulent; Basustaoglu, Ahmet; Öztürk, Recep; Mete, Bilgül; Tasova, Yesim; Kibar, Filiz; Topçu, Ayse Willke; Dündar, Devrim Ozturk; Ünal, Serhat; Gür, Deniz; Ural, Onur; Inci Tuncer, E.; Usluer, Gaye; Durmaz, Gül; Yuce, Ayse; Gülay, Zeynep; Brown, Erwin; Brown, Nick; Dryden, Matthew; Gould, Kate; Guleri, Achyut; Morgan, Marina; Mulla, Rohinton; Swann, Andrew |
| Publisher Information: |
Oxford University Press |
| Publication Year: |
2011 |
| Collection: |
HighWire Press (Stanford University) |
| Subject Terms: |
Original research |
| Description: |
Objectives To assess the in vitro activity of ceftobiprole and comparators against a recent collection of Gram-positive and Gram-negative pathogens, in order to detect potential changes in susceptibility patterns, and to evaluate the Etest assay for ceftobiprole susceptibility testing. Methods Contemporary Gram-positive and Gram-negative isolates (excluding extended-spectrum β-lactamase-producing isolates) from across Europe and the Middle East were collected, and their susceptibility to ceftobiprole, vancomycin, teicoplanin, linezolid, ceftazidime and cefepime was assessed using the Etest method. Quality testing [using Etest and broth microdilution (BMD)] was conducted at a central reference laboratory. Results Some 5041 Gram-positive and 4026 Gram-negative isolates were included. Against Gram-positive isolates overall, ceftobiprole had the lowest MIC 50 (0.5 mg/L), compared with 1 mg/L for its comparators (vancomycin, teicoplanin and linezolid). Against methicillin-resistant Staphylococcus aureus , all four agents had a similar MIC 90 (2 mg/L), but ceftobiprole had a 4-fold better MIC 90 (0.5 mg/L) against methicillin-susceptible strains. Only 38 Gram-positive isolates were confirmed as ceftobiprole resistant. Among Gram-negative strains, 86.9%, 91.7% and 95.2% were susceptible to ceftobiprole, ceftazidime and cefepime, respectively. Pseudomonas aeruginosa was less susceptible to all three antimicrobials than any other Gram-negative pathogen. There was generally good agreement between local Etest results and those obtained at the reference laboratory (for ceftobiprole: 86.8% with Gram-negatives; and 94.7% with Gram-positives), as well as between results obtained by BMD and Etest methods (for ceftobiprole: 98.2% with Gram-negatives; and 98.4% with Gram-positives). Conclusions Ceftobiprole exhibits in vitro activity against a wide range of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. No changes in its known susceptibility profile were identified. |
| Document Type: |
text |
| File Description: |
text/html |
| Language: |
English |
| Relation: |
http://jac.oxfordjournals.org/cgi/content/short/66/1/151; http://dx.doi.org/10.1093/jac/dkq397 |
| DOI: |
10.1093/jac/dkq397 |
| Availability: |
http://jac.oxfordjournals.org/cgi/content/short/66/1/151; https://doi.org/10.1093/jac/dkq397 |
| Rights: |
Copyright (C) 2011, The British Society for Antimicrobial Chemotherapy |
| Accession Number: |
edsbas.AB7B99C7 |
| Database: |
BASE |